The newly unsealed lawsuit highlights potential False Claims Act violations and comes from five whistleblowers who previously worked on Xolair promotion at the companies. More: Whistleblower suit accuses Genentech, Novartis of running decades-long kickback scheme on allergy med Xolair Source:
read moreWhile dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as pipelines bring massive sales opportunities to bear. More: Big obesity bets and China's
read moreThe Claudin18.2-targeted therapy is the first CAR-T to win global approval in a solid tumor. More: CARsgen makes history as China approves world's first CAR-T therapy for solid tumors Source: fierce
read moreAmid efforts in Germany to retool the country’s drug spending, the U.S. is launching an investigation into what the Office of the United States Trade Representative has branded “persistent underpayment” by the European nation for new meds. More: US to
read morePfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the biotech, although the U.K. marketing watchdog overturned its severest criticism on appeal. More: Alnylam scolded over promotional activity after Pfizer complaint Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals